Hahn, M
Böttcher, S
Dietrich, S
Hegenbart, U
Rieger, M
Stadtherr, P
Bondong, A
Schulz, R
Ritgen, M
Schmitt, T
Tran, T H
Görner, M
Herth, I
Luft, T
Schönland, S
Witzens-Harig, M
Zenz, T
Kneba, M
Ho, A D
Dreger, P
Article History
Received: 20 January 2015
Revised: 21 May 2015
Accepted: 22 May 2015
First Online: 6 July 2015
Competing interests
: PD is Board member of the European Group for Blood and Marrow Transplantation (EBMT) and the German Working Group for Marrow and Blood Stem Cell Transplantation (DAG-KBT); has been working as Consultant for Chugai Pharma and Riemser Pharma; has worked on Advisory Boards for Janssen and Gilead; and has received honoraria from Gilead, Glaxo Smith Kline, Janssen, Mundipharma and Riemser Pharma. MH has received research support from Riemser Pharma. IH has received research support from Medac GmbH and Roche Pharma. SB received research support from Roche, AbbVie and Celgene and honoraria from Roche and AbbVie, and has been working as Consultant for Roche. The remaining authors declare no conflicts of interest.